COVID-19 Outlook: Variants, Boosters, And Being ‘Worse Off’ For Next Pathogens
US FDA’s Peter Marks, Pfizer’s Mikael Dolsten and other experts discuss what is being done to prepare for the future, worries about higher fatality rates, and what 2023 might look like.
You may also be interested in...
A modeling study, an analysis of a dozen clinical trials and a survey of 400 clinical trial executives all show how using decentralized elements in trials can result in faster, less expensive and more engaging research.
The White House ‘Biotechnology’ initiative is very broadly focused, with non-health sectors receiving the bulk of the attention. The US FDA’s role is small – but it could further boost attention to efforts to encourage adoption of advanced manufacturing.
Is a 100-day timeline for developing vaccines against newly identified health threats a realistic proposition? Attendees at this week’s Global Pandemic Preparedness Summit certainly think so. Meanwhile, Moderna has said it will build its first African mRNA plant in Kenya, and has pledged “never” to enforce its vaccine patents in lower-income countries.